In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency ...

Keryx’s Auryxia has so far struggled to get off the ground. But after winning its second FDA approval, the company’s now prepping for a launch that it thinks can take the drug to the next level.

Keryx Biopharmaceuticals, Inc. KERX announced that the nation’s largest Medicare Part D plan sponsor has added Auryxia (ferric citrate) to its Medicare Part D plan formularies. Keryx’s share price has ...

Keryx Biopharmaceuticals Inc.’s KERX shares rallied 3.8% on the company’s announcement of additional data from a phase III study on Auryxia for the treatment of iron deficiency anemia (IDA) in ...

BOSTON, MA, June 24, 2015 – Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced ...

(RTTNews) - Akebia Therapeutics, Inc. (AKBA) Thursday announced positive results from its Phase 4 collaborative study, IMPACT, which examined the effects of Auryxia or ferric citrate as the primary ...

We issued an updated research report on Keryx Biopharmaceuticals, Inc. KERX on Sep 26, 2017. Notably, the company’s only marketed product, Auryxia (ferric citrate) is approved in the United States for ...

Please provide your email address to receive an email when new articles are posted on . The share price of dialysis drug maker Keryx Biopharmaceuticals went down almost 48% this week after the company ...

Please provide your email address to receive an email when new articles are posted on . The U.S. Food and Drug Administration has accepted for review the supplemental New Drug Application for Keryx ...

DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Auryxia" drug pipelines has been added to ResearchAndMarkets.com's offering. Auryxia (ferric citrate; Keryx Biopharmaceuticals/Japan Tobacco/Torii ...